3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
106
Neoplasm Metastasis
9
Ovarian Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Prostatic Neoplasms
2
Obesity
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Carcinoma In Situ
2
Breast Cancer Metastatic
2
Arthralgia
2
Triple Negative Breast Neoplasms
1
Sexuality
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Primary Breast Cancer ER+ve
1
Premenopausal Breast Cancer
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Pain
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Beast Cancer
1
Locoregional Recurrence
1
Hyperglycemia
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hormone Receptor Positive Malignant Neoplasm of Breast
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Interventions
palbociclib
1
exemestane
1
delta 24-sterol reductase
1
Vinorelbine
1
Therapeutics
1
Tamoxifen
1
Standard of Care
1
Risk Assessment
1
Paclitaxel
1
Letrozole
1
Influenza Vaccines
1
Fulvestrant
1
Focus Groups
1
Epirubicin
1
Drug Therapy
1
Counseling
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Patient Acceptance of Health Care
×
exemestane
×
Clear all
NCT03355157
2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4
Completed
130 enrolled